After reviewing the relative frequency of the causes of allogeneic blood transfusion-related
mortality in the United States today, we present 6 possible strategies for further reducing …

There is an ongoing debate whether platelet concentrates (PCs) prepared from either whole‐
blood donations or by plateletpheresis are superior. Usage of these two product types varies …

Purpose To provide evidence-based guidance on the use of platelet transfusion in people
with cancer. This guideline updates and replaces the previous ASCO platelet transfusion …

The ability to create a platelet product for transfusion purposes has existed for more than 50
years, 1 and has contributed to fundamental changes in the practice of transfusion medicine …

2011 年国际输血协会(ISBT) 确认了P1PK 血型系统的抗原, 命名为P1PK, 编号003.
确认该系统有3 个抗原, 分别是: P1, PK, NOR. 本文就目前对P1PK 系统抗原的研究进展 …

Platelet characteristics, such as platelet dose, platelet source (apheresis vs pooled), platelet
donor-recipient ABO compatibility, and duration of platelet storage, can affect …

Platelet transfusions are used in clinical practice to prevent and treat haemorrhage in
thrombocytopenic patients or patients with severe platelet dysfunction. In the UK, and …

Patients with hypoproliferative thrombocytopenia are at an increased risk for hemorrhage
and alloimmunization to platelets. Updated guidance for optimizing platelet transfusion …

Background Platelet transfusions are used in modern clinical practice to prevent and treat
bleeding in people who are thrombocytopenic due to bone marrow failure. Although …

Platelet transfusion refractoriness due HLA alloimmunization presents a significant medical
problem, particularly among multiply transfused patients with hematologic malignancies and …